Insider · SEC Form 4 filer

RA Capital Healthcare Fund LP

Past buys: 2 of 6 beat

Companies

Where they file as an insider

Vor Biopharma (VOR) 10% owner Latest filing Aug 24, 2026
Artiva Biotherapeutics (ARTV) Director, 10% owner Latest filing Jul 31, 2026
Inhibikase Therapeutics (IKT) 10% owner Latest filing Jul 29, 2026
Hemab Therapeutics (COAG) 10% owner Latest filing May 11, 2026
Adicet Bio (ACET) 10% owner Latest filing Feb 20, 2026
Mineralys Therapeutics (MLYS) Director Latest filing Feb 19, 2026
Evommune (EVMN) Director Latest filing Feb 17, 2026
SpyGlass Pharma (SGP) Director, 10% owner Latest filing Feb 9, 2026

And 11 more companies with older filings.

Track record

Did their buys beat the typical stock?

Open-market buys14
Quarters checked 6 months later6
Beat the typical stock 2 of 6
Quarters too new to check1

2 of 6 checked quarters beat the typical stock. A past record is data, not a forecast.

Artiva Biotherapeutics (ARTV) Bought Jul 16–31, 2026 · $1.89M · 206,122 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
SpyGlass Pharma (SGP) Bought Feb 9, 2026 · $59M · 3.69M shares Behind typical Mar 31, 2026 $25.91 → Sep 30, 2026 $26.00 · +0.3% (typical stock +1.7%)
Climb Bio (CLYM) Bought Jan 5, 2026 · $24.9K · 7,111 shares Beat typical Mar 31, 2026 $6.85 → Sep 30, 2026 $11.47 · +67.4% (typical stock +1.7%)
PepGen (PEPG) Bought Sep 26, 2025 · $30M · 9.38M shares Behind typical Sep 30, 2025 $4.62 → Mar 31, 2026 $1.77 · −61.7% (typical stock −3.4%)
Tyra Biosciences (TYRA) Bought Jun 9, 2025 · $1.9M · 186,850 shares Beat typical Jun 30, 2025 $9.57 → Dec 31, 2025 $26.29 · +174.7% (typical stock +2.1%)
Janux Therapeutics (JANX) Bought Mar 5–7, 2025 · $25.3M · 824,041 shares Behind typical Mar 31, 2025 $27.00 → Sep 30, 2025 $24.44 · −9.5% (typical stock +7.3%)
Tyra Biosciences (TYRA) Bought Nov 8, 2024 · $19.8M · 1.22M shares Behind typical Dec 31, 2024 $13.90 → Jun 30, 2025 $9.57 · −31.2% (typical stock −3.4%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist